PIK3CA and urinary bladder cancer: Ross et al. evaluated the role of the PI3K inhibitor (GDC0941) in the treatment of bladder cancer and showed that bladder cancer cells with activated PIK3CA mutations were sensitive to PI3K inhibitors [45].